jbog
I was expecting to see some use of Cash. Buyback also makes ton of sense, esp if they have the cash until 2014 to get Copaxone and they are confident to rope in partner for a reasonably favorable partnership deal on FOB. If they are going out and presenting to investors and painting such a rosy picture in their C.C on their FOB technology and the certainty of Copaxone approval, they better put money where the money is, esp when they are sitting with this HUGE cash
It will be interesting to see if TEVA makes a unsolicited bid on MNTA at double it's current price
* TEVA is known to be acquirer
* MNTA would be very easy to integrate. Really, there are 3 products
* Assume TL is nowhere near approval(and nobody else is) like most in this board believe, then such a transaction would immediately accretive to TEVA. TEVA trades around 12 P.E. MNTA around P.E of 7 (assuming conservatively EPS of 2.5 after all NOL's are done)
And factor in potential earnings effect to TEVA on copaxone, and FOB characterization value that MNTA has, TEVA can easily pay $34
* not sure contractually(with NVS) if they can do such a deal esp with competitor(TEVA)
Good luck C.W